Quick Answer
Prelude Therapeutics Inc reported Stockholders Equity of $68.64 million for fiscal year 2025.
Prelude Therapeutics Inc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $68.64M | -47.8% |
| 2024 | $131.46M | -44.6% |
| 2023 | $237.09M | +21.3% |
| 2022 | $195.44M | -31.6% |
| 2021 | $285.90M | +34.7% |
| 2020 | $212.18M | +529.4% |
| 2019 | -$49.41M | -117.7% |
| 2018 | -$22.69M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $58.53M | -62.6% | -22.8% |
| June 30, 2025 | $75.84M | -58.4% | -26.5% |
| March 31, 2025 | $103.18M | -51.0% | -21.5% |
| December 31, 2024 | $131.46M | -44.6% | -16.0% |
| September 30, 2024 | $156.43M | -34.3% | -14.2% |
| June 30, 2024 | $182.28M | -30.4% | -13.5% |
| March 31, 2024 | $210.73M | +20.2% | -11.1% |
| December 31, 2023 | $237.09M | +21.3% | -0.5% |
- Prelude Therapeutics Inc showed a decrease of -47.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Prelude Therapeutics Inc’s stockholders equity has grown by 402.5% (from -$22.69 million to $68.64 million).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: